Stocks Health care SRTS
NASDAQ · Health careSensus Healthcare, Inc. (SRTS)
Sensus Healthcare, Inc. brought in $17.5M of revenue over the twelve months to June 30, 2026, down 53.4% from a year earlier. It posted a net loss of $15.5M. Operating cash flow minus capital spending left $332K of free cash flow in fiscal 2025. At June 30, 2026 it held $15.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Sensus Healthcare, Inc.
- Net worth
- Sensus Healthcare, Inc. has a market value (market cap) of $52.3M at the latest share price, and shareholders' equity of $36.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $27.5M (-34.3% year on year), with a net loss of $7.7M. Over the 12 months to June 30, 2026: revenue $17.5M, net loss $15.5M.
- Cash flow
- In fiscal 2025 operations brought in $528K of cash; after $196K of capital spending, free cash flow was $332K.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Sensus Healthcare, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Sensus Healthcare, Inc. does
Sensus Healthcare, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker SRTS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $27.5M | -$7.7M | -$0.47 | $332K |
| 2024 | $41.8M | $6.6M | $0.41 | -$1.1M |
| 2023 | $24.4M | $485K | $0.03 | -$2.4M |
| 2022 | $44.5M | $24.2M | $1.46 | -$1.6M |
| 2021 | $27M | $4.1M | $0.25 | -$414K |
| 2020 | $9.6M | -$6.8M | -$0.42 | -$793K |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SRTS ranks in Health care
Latest SEC filings
What Sensus Healthcare, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 69% to $2.3M versus the same quarter last year; diluted EPS -$0.53 versus -$0.06.
- August 13, 2026
- June 5, 2026
- June 2, 2026
- May 18, 2026
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 59% to $3.4M versus the same quarter last year; diluted EPS -$0.16 versus -$0.16.
- May 7, 2026
- April 29, 2026Proxy statement DEF 14A
- March 4, 2026Annual report 10-K · period to December 31, 2025Revenue fell 34% to $27.5M versus the prior year; diluted EPS -$0.47 versus $0.41.
- February 12, 2026
What is SRTS worth? A DCF from its reported cash flow
Insider trades
What the people running Sensus Healthcare, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $563.5K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 31, 2026 | Sachetta EricDirector | Bought | 27,304 | $96.6K |
| August 28, 2026 | Sachetta EricDirector | Bought | 37,537 | $129K |
| August 27, 2026 | Sachetta EricDirector | Bought | 10,925 | $34.8K |
| August 26, 2026 | Sachetta EricDirector | Bought | 9,708 | $31.9K |
| August 24, 2026 | Sachetta EricDirector | Bought | 34,697 | $112.9K |
| August 21, 2026 | Sachetta EricDirector | Bought | 7,000 | $22.8K |
| August 20, 2026 | Sardano Joseph CCHIEF EXECUTIVE OFFICER, Director | Bought | 20,000 | $60.5K |
| August 20, 2026 | Sachetta EricDirector | Bought | 24,000 | $75.1K |
Who owns SRTS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Edwin L. Solot, Jr.13G, passive | 7.6% | February 7, 2025 |
| Joseph C. Sardano13G, passive | 7.1% | May 22, 2025 |
Largest institutional holders
Insiders
5 insiders reported holding 1,735,043 shares in total, about $5.5M at the last price.
| Holder | Shares |
|---|---|
| Sardano Joseph CCHIEF EXECUTIVE OFFICER, Director | 1,220,293 |
| Sachetta EricDirector | 294,784 |
| Sardano MichaelPRESIDENT AND GENERAL COUNSEL, Director | 159,8391,000 held indirectly |
| Rampolla JavierCHIEF FINANCIAL OFFICER | 48,114 |
| Martinez MagdalenaCHIEF OPERATING OFFICER | 12,013 |
Questions about SRTS
What does Sensus Healthcare, Inc. do?
Sensus Healthcare, Inc. is a company in the Health care sector, listed on NASDAQ as SRTS. Its shares trade on NASDAQ under the ticker SRTS.
What is Sensus Healthcare, Inc.'s net worth?
Sensus Healthcare, Inc. has a market value (market cap) of $52.3M at the latest share price, and shareholders' equity of $36.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Sensus Healthcare, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $15.5M on revenue of $17.5M.
How much revenue does Sensus Healthcare, Inc. make?
Over the twelve months to June 30, 2026 Sensus Healthcare, Inc. reported revenue of $17.5M. That is 53.4% less than a year earlier.
When did Sensus Healthcare, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 31, 2026.
When is Sensus Healthcare, Inc.'s next earnings report?
Sensus Healthcare, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare SRTS with
Follow SRTS
Get an email when Sensus Healthcare, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Sensus Healthcare, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.